Article Versions Notes

Kakehashi A, Suzuki S, Nishidoi Y, Hagihara A, Ikenaga H, Shiota M, Qiu G, Noura I, Kuwae Y, Vachiraarunwong A, et al. The Impact of Peroxiredoxin 3 on Molecular Testing, Diagnosis, and Prognosis in Human Pancreatic Ductal Adenocarcinoma. Cancers. 2025; 17(13):2212. https://doi.org/10.3390/cancers17132212

Kakehashi, Anna, Shugo Suzuki, Yusaku Nishidoi, Atsushi Hagihara, Hiroko Ikenaga, Masayuki Shiota, Guiyu Qiu, Ikue Noura, Yuko Kuwae, Arpamas Vachiraarunwong, and et al. 2025. "The Impact of Peroxiredoxin 3 on Molecular Testing, Diagnosis, and Prognosis in Human Pancreatic Ductal Adenocarcinoma" Cancers 17, no. 13: 2212. https://doi.org/10.3390/cancers17132212

Kakehashi, A., Suzuki, S., Nishidoi, Y., Hagihara, A., Ikenaga, H., Shiota, M., Qiu, G., Noura, I., Kuwae, Y., Vachiraarunwong, A., Fujioka, M., Gi, M., Kawada, N., & Wanibuchi, H. (2025). The Impact of Peroxiredoxin 3 on Molecular Testing, Diagnosis, and Prognosis in Human Pancreatic Ductal Adenocarcinoma. Cancers, 17(13), 2212. https://doi.org/10.3390/cancers17132212